|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial显示文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting. | Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu | 2021 | Cancer Communications2021，41，9： | 5 |
| 2 | SOCS3 Attenuates GM-CSF/IFN-γ-Mediated Inflammation During Spontaneous Spinal Cord Regeneration显示文摘SOCS3,a feedback inhibitor of the JAK/STAT signal pathway,negatively regulates axonal regrowth and inflammation in the central nervous system(CNS).Here,we demonstrated a distinct role of SOCS3 in the injured spinal cord of the gecko following tail amputation.Severing the gecko spinal cord did not evoke an inflammatory cascade except for an injury-stimulated elevation of the granulocyte/macrophage colony-stimulating factor(GM-CSF) and interferon gamma(IFN-γ) cytokines.Simultaneously,the expression of SOCS3 was upregulated in microglia,and unexpectedly not in neurons.Enforced expression of SOCS3 was sufficient to suppress the GMCSF/IFN-γ-driven inflammatory responses through its KIR domain by attenuating the activities of JAK1 and JAK2.SOCS3 was also linked to GM-CSF/IFN-y-induced crosstolerance.Transfection of adenovirus overexpressing SOCS3 in the injured cord resulted in a significant decrease of inflammatory cytokines.These results reveal a distinct role of SOCS3 in the regenerating spinal cord,and provide new hints for CNS repair in mammals. | Xuejie Zhang Bingqiang He Hui Li Yingjie Wang Yue Zhou Wenjuan Wang Tiancheng Song Nan Du Xingxing Gu Yi Luo Yongjun Wang | 2020 | Neuroscience Bulletin2020，36，7： | 3 |
| 3 | RNA Interference-Mediated Gene Silencing of Vascular Endothelial Growth Factor显示文摘OBJECTIVE To inhibit the expression of the vascular endothelial growth factor (VEGF) by RNA interference, and to observe the effect in different cells line. METHODS Using the services of E-RNAi, we designed and constructed two kinds of shRNAs expression vectors which were aimed at the VEGF gene. These vectors were then transfected into HEK293, colon cancer HT29, Hela and HepG2 cells by LipofectamineTM 2000. The level of VEGF mRNA was determined by RT-PCR and Northern blotting and the VEGF expression was examined by immunofluoresence staining. RESULTS The two kinds of VEGF specific shRNAs expression vectors were found to efficiently inhibit the expression of VEGF in HEK293 and HT29 cells by RT-PCR analysis, with inhibition rates of 72% and 42%, respectively; but the inhibition rates were reduced to 28% in Hela cells and 13% in HepG2 cells. Northern blotting showed that the inhibition rates of VEGF mRNA expression were 88% and 89% in HEK293 and HT29 cells, respectively. The inhibition rate of VEGF protein expression in HT29 cells was 73% based on immunofluoresence staining. CONCLUSION The expression of VEGF was inhibited by RNA interference, but differed with various cells lines, showing that RNA interference was cell-line dependent. | Tiejun Li Jianning Song Kai Kang Zanlan Hu Tongchuan He Bingqiang Zhang Caiquan Zhang | 2006 | Chinese Journal of Clinical Oncology2006，3，6： | 1 |
| 4 | Simple and rapid conversion of silicon carbide to nanodiamonds at ambient pressure显示文摘Nanodiamonds(NDs)were prepared under ambient pressure by sublimation decomposition of silicon carbide in an intermediate frequency furnace for only 8 min.The synthesis proceeded in the temperature range of 2600-2800℃ without any catalyst or highly active gas components(such as H2,alkane,and halogen).The conversion began at 2600℃ and produced NDs with particle sizes in the range of 1-5 nm with a uniform particle shape and excellent dispersion.The linear reaction kinetics allowed for rapid transformation to any depth with reasonable control of the temperature.The linear rate constant(K_(l))for the reaction at 2800℃ was 37.5 mm/h,which is 31.2 times that of the reaction at 2600℃.The Si C sublimation decomposition produced carbon atoms that filled the Si C lattice vacancies or were combined with the suspended carbon chain bonds to form sp3 carbon,while the diffusion of amorphous carbon atoms promoted nucleation and growth of diamond.High-resolution transmission electron microscopy analysis indicated that the NDs were separated from the Si C matrix by break-off due to propagation of the reaction front.This Si C sublimation decomposition method is considered simple,fast,environmentally friendly and promising for industrial-scale production. | Cheng Yang Bingqiang Wei Kejian He Ping Xu Xiangmin Xie Kai Tong Chen Zeng Yafeng Wang Xiaodong Wang Jinping Liu Mingyu Zhang Zhe'an Su Qizhong Huang | 2021 | Journal of Materials Science & Technology2021，，35： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员